Fritextsökning
Innehållstyper
-
Sustainability at Festo
On the Way to the Net Zero Era - New Sustainability Report published
-
Large study on milk: Risky for women but not for men
The risk of ischemic heart disease (IHD) and acute myocardial infarction (MI) increased for women with milk intake levels higher than 2 glasses per day, while n...
-
Lilly recruits top Swedish researcher in Alzheimer´s
One of Sweden's leading Alzheimer's researchers, Oskar Hansson, has been recruited by pharma giant Eli Lilly and will be moving to the USA.
-
Optimism hos Astra Zeneca – ”Ökande efterfrågan i alla nyckelregioner”
Astra Zeneca överraskade positivt när bolaget redovisade resultaten för fjolårets fjärde kvartal. Samtidigt kom information om att bolaget har obetalda skatter i Kina.
-
Bioscience – Groundbreaking Research & Diagnostics: Stockholm (2025)
-
Elevating 3D characterization with enhanced performance and efficiencies
Introducing the ZEISS VersaXRM 730 3D X-ray microscope.
-
Lifs Sofia Wallström tar plats i EFPIA:s styrelse
Lifs vd Sofia Wallström har valts in i styrelsen för den europeiska branschorganisationen EFPIA.
-
Sneak Peek of ZEISS Metrology Expert Tips Season 2
The second season of the video series starts in January 2026, but you can discover more about the highlights of Season 2 now.
-
Merck investerar över 70 miljarder dollar i USA
Merck & Co följer flera andra globala läkemedelsjättar och pumpar in hundratals miljarder kronor i nya produktionsanläggningar i USA.
-
Ingrid Lönnstedt: ”The confidence interval and its width”
Always keep an eye on the width of your and others’ confidence intervals, writes Ingrid Lönnstedt in a science column.
-
The FDA’s new transparency policy (Part 3)
As transparency and consistency become increasingly emphasized by the FDA, medical device manufacturers must approach their submissions with both thoroughness a...
-
Novo Nordisk skrotar distansarbete
Vid årsskiftet slopar Novo Nordisk möjligheten till distansarbete. Enligt bolagets nya vd ska det påskynda beslutsfattandet och förbättra den kommersiella genom...
-
WHO: Pandemiavtal klart
Tre år av förhandlingar har lett fram till ett utkast på ett avtal som ska göra världen bättre förberedd på framtida pandemier.
-
Conjugate Planes in Microscopy
Knowledge Article from ZEISS.
-
“Conducting research at universities is becoming more and more like working at a research hotel”
The government wants Swedish research to focus on excellence and innovation, but can the two be combined? Life Science Sweden talks to Anna Falk, a professor at...
-
Revealing the secrets of a part
CT inspection in automation technology at Festo.
-
From lab to patient – the art of developing new antibody therapies
For 25 years, Danish company Genmab has been developing antibodies and has managed to get several drugs all the way to the patient. Esther Breij has been along ...
-
Chiesi satsar på leverinriktad genterapi
Läkemedelsbolaget Chiesi tar ytterligare kliv in på genterapiområdet genom ett licensavtal med amerikanska Arbor Biotechnologies.
-
Efter förseningen – nu lämnar Xspray in uppdaterad FDA-ansökan
Forskningsbolaget Xspray Pharma har nu lämnat in en uppdaterad FDA-ansökan om godkännande för leukemibehandlingen Dasynoc.
-
The future of healthcare in focus: ”Together, things happen”
In march, it’s once again time for Fokus Patient, an event for the industry where the patients’ perspective takes center stage. It’s a great way to spread knowl...
-
Medivir CEO on upcoming study: ”It's about working together with others”
Medivir is a small company with a big task: to take its drug candidate, via extensive clinical studies, all the way to a patient group that currently lacks appr...
-
Astra Zeneca’s Sweden CEO: “We have great faith in our portfolio”
It all started with a summer job as an operator at Astra’s chemical factory in Snäckviken, just outside Södertälje. More than three decades and countless differ...
-
New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Copenhagen (2026)
-
Klartecken för Pharmnovo – kan gå vidare med studie i nervsmärta
Pharmnovo har fått godkännande från spanska myndigheter att genomföra en fas IIa-studie för att pröva bolagets läkemedelskandidat för behandling av neuropatisk smärta.